A collaboration of 41 international clinical centres that manage patients affected with inherited retinal diseases (IRDs), supported by the US Foundation Fighting Blindness (FFB), have… Read More »Foundation Fighting Blindness (FFB) have presented genetic data on IRDs for almost 34,000 patients and families within international sites.
A systematic review and meta-analysis, performed by researchers at the School of Medicine, College of Medicine, Taipei Medical University, have shown a strong association between… Read More »Retinal vein occlusion (RVO) appears to associate with an increased risk of myocardial infarction for patients,
Researchers at the Department of Translational Medicine, University of Ferrara, Italy, and colleagues in the ERN-EYE Network, have published paper on the first study to… Read More »Real-world impacts of an observational study on X-linked retinitis pigmentosa (XLRP) patients’ experience, supported by the ERN-EYE Network.
Researchers at the Department of Ophthalmology, Seoul National University College of Medicine, South Korea, have conducted a study to evaluate the national incidence of rare… Read More »A nationwide study on the incidence of rare retinal diseases in South Korea reports 1.1M clinical records.
Researchers at the Casey Eye Institute, Oregon Health & Science University (OHSU), Portland, USA, have provided formal results of a Phase 1/2 study, published at… Read More »A phase 1/2 multi-centre study provides results for the treatment of XLRP, promising a Phase 2/3 study to progress in 2025.
Researchers at the Department of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of Korea, have outlined an increasing future burden of depressive disorders, providing… Read More »An investigation of the association between Retinitis pigmentosa (RP) and depressive disorder, including a call for practical training and methods.
Clinical researchers at the Department of Ophthalmology, Bascom Palmer Eye Institute, in the University of Miami, Florida, have presented an update on clinical trial endpoints… Read More »An update of clinical trial endpoints provide a dynamic trial environment across a range of inherited retinal degenerations (IRDs).
Clinical researchers at the Center for Hereditary Retinal Degenerations, Scheie Eye Institute, University of Pennsylvania, Philadelphia, have published the results of a Phase 1/2 study… Read More »Dose escalation study of ASTN-101 (AAV5-GUCY2D) for LCA1 patients provide improvement in FST and BCVA (Phase 1/2).
An international clinical research consortium has reported recommendations on endpoints and design of clinical trials in USH2A-related retinal degenerations. The study, supported by the US… Read More »Endpoints and clinical trial design for IRDs and USH2A reporting outcomes from a natural history study.
EURETINA Congress, Barcelona – Sept. 20th, 2024: Prof. M. Dominick Fischer, based at Nuffield Laboratory of Ophthalmology, University of Oxford and the Oxford Eye Hospital,… Read More »Real world data from the treatment by voretigene neparvovec (Luxturna) of LCA2-RPE65 patients across 24 countries.
